Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Research & Development (2019 - 2025)

Keros Therapeutics' Research & Development history spans 7 years, with the latest figure at $17.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 60.75% year-over-year to $17.9 million; the TTM value through Dec 2025 reached $129.6 million, down 25.33%, while the annual FY2025 figure was $129.6 million, 25.33% down from the prior year.
  • Research & Development reached $17.9 million in Q4 2025 per KROS's latest filing, down from $19.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $49.2 million in Q3 2024 to a low of $10.0 million in Q2 2021.
  • Average Research & Development over 5 years is $29.0 million, with a median of $28.0 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 133.21% in 2022, then tumbled 60.75% in 2025.
  • A 5-year view of Research & Development shows it stood at $18.8 million in 2021, then skyrocketed by 32.04% to $24.9 million in 2022, then soared by 50.77% to $37.5 million in 2023, then rose by 21.71% to $45.6 million in 2024, then crashed by 60.75% to $17.9 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Research & Development are $17.9 million (Q4 2025), $19.5 million (Q3 2025), and $43.5 million (Q2 2025).